Anupam Rama
Stock Analyst at JP Morgan
(3.39)
# 958
Out of 4,859 analysts
265
Total ratings
42.79%
Success rate
4.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COGT Cogent Biosciences | Maintains: Overweight | $21 → $25 | $7.10 | +252.11% | 5 | May 29, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Overweight | $63 → $66 | $21.72 | +203.87% | 8 | May 22, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $169 → $84 | $37.51 | +123.94% | 12 | May 20, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $30 → $28 | $4.07 | +587.96% | 4 | Mar 28, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $104 → $117 | $39.38 | +197.11% | 3 | Mar 27, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $183 → $184 | $124.54 | +47.74% | 17 | Mar 26, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $44 → $50 | $39.31 | +27.19% | 9 | Mar 24, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $39 → $41 | $10.40 | +294.23% | 10 | Mar 20, 2025 | |
| ZLAB Zai Lab | Maintains: Overweight | $44 → $51 | $43.02 | +18.55% | 12 | Mar 13, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $12 → $11 | $4.55 | +142.02% | 7 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $34 | $6.71 | +406.71% | 4 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $42 | $23.44 | +79.18% | 11 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $77 → $71 | $21.66 | +227.79% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $54 | $18.83 | +186.78% | 16 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $14.40 | +205.56% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $9.67 | +86.14% | 8 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $22 | $9.33 | +135.80% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $12.35 | +142.91% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $17 | $6.04 | +181.46% | 13 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.10 | - | 7 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $28.65 | +39.62% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $125 | $77.08 | +62.18% | 6 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $0.93 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $64 → $68 | $46.77 | +45.41% | 5 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $10 | $6.56 | +52.44% | 7 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.33 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $2.86 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $2.47 | +427.38% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $9 | $0.38 | +2,267.80% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.87 | - | 6 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.38 | - | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $8.81 | +2,736.17% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.44 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $33.39 | +73.70% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $10.62 | +12.99% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $5.24 | +606.78% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $55.70 | -1.25% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $1.51 | +1,754.30% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $34.42 | +56.89% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.45 | +9,989.69% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $14.14 | +90.95% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $10.00 | +300.00% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $305.63 | -55.17% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $39 | $4.68 | +733.33% | 1 | Dec 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $7.83 | +513.42% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $10.26 | - | 2 | May 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $18 | $0.80 | +2,149.72% | 2 | Mar 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.82 | +3,545.20% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $50.54 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.66 | - | 2 | Jul 21, 2017 |
Cogent Biosciences
May 29, 2025
Maintains: Overweight
Price Target: $21 → $25
Current: $7.10
Upside: +252.11%
IDEAYA Biosciences
May 22, 2025
Maintains: Overweight
Price Target: $63 → $66
Current: $21.72
Upside: +203.87%
Sarepta Therapeutics
May 20, 2025
Maintains: Overweight
Price Target: $169 → $84
Current: $37.51
Upside: +123.94%
Olema Pharmaceuticals
Mar 28, 2025
Maintains: Overweight
Price Target: $30 → $28
Current: $4.07
Upside: +587.96%
Ultragenyx Pharmaceutical
Mar 27, 2025
Maintains: Overweight
Price Target: $104 → $117
Current: $39.38
Upside: +197.11%
Neurocrine Biosciences
Mar 26, 2025
Maintains: Overweight
Price Target: $183 → $184
Current: $124.54
Upside: +47.74%
BridgeBio Pharma
Mar 24, 2025
Maintains: Overweight
Price Target: $44 → $50
Current: $39.31
Upside: +27.19%
Syndax Pharmaceuticals
Mar 20, 2025
Maintains: Overweight
Price Target: $39 → $41
Current: $10.40
Upside: +294.23%
Zai Lab
Mar 13, 2025
Maintains: Overweight
Price Target: $44 → $51
Current: $43.02
Upside: +18.55%
Solid Biosciences
Mar 13, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $4.55
Upside: +142.02%
Mar 5, 2025
Maintains: Overweight
Price Target: $39 → $34
Current: $6.71
Upside: +406.71%
Mar 5, 2025
Maintains: Overweight
Price Target: $36 → $42
Current: $23.44
Upside: +79.18%
Mar 4, 2025
Maintains: Overweight
Price Target: $77 → $71
Current: $21.66
Upside: +227.79%
Mar 4, 2025
Maintains: Overweight
Price Target: $50 → $54
Current: $18.83
Upside: +186.78%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $14.40
Upside: +205.56%
Feb 26, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $9.67
Upside: +86.14%
Feb 26, 2025
Maintains: Overweight
Price Target: $21 → $22
Current: $9.33
Upside: +135.80%
Feb 25, 2025
Initiates: Overweight
Price Target: $30
Current: $12.35
Upside: +142.91%
Nov 12, 2024
Maintains: Overweight
Price Target: $16 → $17
Current: $6.04
Upside: +181.46%
Nov 11, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.10
Upside: -
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $28.65
Upside: +39.62%
Oct 4, 2024
Maintains: Overweight
Price Target: $100 → $125
Current: $77.08
Upside: +62.18%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $0.93
Upside: -
Sep 4, 2024
Maintains: Overweight
Price Target: $64 → $68
Current: $46.77
Upside: +45.41%
Aug 6, 2024
Maintains: Neutral
Price Target: $12 → $10
Current: $6.56
Upside: +52.44%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.33
Upside: -
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $2.86
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $2.47
Upside: +427.38%
Aug 16, 2023
Maintains: Neutral
Price Target: $8 → $9
Current: $0.38
Upside: +2,267.80%
Jul 25, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.87
Upside: -
Nov 10, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.38
Upside: -
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $8.81
Upside: +2,736.17%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.44
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $33.39
Upside: +73.70%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $10.62
Upside: +12.99%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $5.24
Upside: +606.78%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $55.70
Upside: -1.25%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $1.51
Upside: +1,754.30%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $34.42
Upside: +56.89%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.45
Upside: +9,989.69%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $14.14
Upside: +90.95%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $10.00
Upside: +300.00%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $305.63
Upside: -55.17%
Dec 24, 2019
Initiates: Overweight
Price Target: $39
Current: $4.68
Upside: +733.33%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $7.83
Upside: +513.42%
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $10.26
Upside: -
Mar 6, 2018
Maintains: Overweight
Price Target: $15 → $18
Current: $0.80
Upside: +2,149.72%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $0.82
Upside: +3,545.20%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $50.54
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $0.66
Upside: -